ProfileGDS5678 / 1440074_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 50% 50% 49% 48% 50% 49% 49% 49% 50% 50% 49% 49% 50% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2653251
GSM967853U87-EV human glioblastoma xenograft - Control 23.1940250
GSM967854U87-EV human glioblastoma xenograft - Control 33.1931250
GSM967855U87-EV human glioblastoma xenograft - Control 43.1158849
GSM967856U87-EV human glioblastoma xenograft - Control 53.0840748
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3041850
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2525649
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1637749
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1614649
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1754950
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1873450
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1443549
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1863449
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.179850